ArticleFrontiers in pharmacology2026
Efficacy, mechanisms, and influence factors of small molecule targeted therapy in treating rheumatoid arthritis: a multi-dimensional clinical, immunological, and ultrasonographic study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) show promise for rheumatoid arthritis (RA), but multi-dimensional efficacy evaluation needs further study. Objective: This study aimed to comprehensively assess tsDMARDs' efficacy in RA and explore factors linked to treatment response. Methods: 123 consecutive active RA patients treated with tsDMARDs for ≥6 months at Suzhou Ninth People's Hospital (January 2023-December 2024) were retrospectively analyzed; 120 were included after exclusions. Clinical efficacy was appraised using the Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP), Clinical Disease Activity Index (CDAI), American College of Rheumatology 20/50/70 (ACR20/50/70), and the overall effective rate. Immunological parameters included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and anti-citrullinated protein antibody (ACPA). Musculoskeletal ultrasound parameters consisted of synovial hypertrophy score assessed by gray-scale ultrasound (GSUS) and synovial vascularity grade assessed by power Doppler ultrasound (PDUS). Correlations between parameters were analyzed, and multivariate logistic regression pinpointed independent risk factors of favorable therapeutic response. Results: Among 120 patients, patients were stratified into effective (n = 78) and non-effective (n = 42) groups, with comparable baseline characteristics (all Conclusion: tsDMARDs effectively improve joint symptoms, reduce disease activity, and enhance articular function in RA patients, potentially supporting personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.